Insulet Corporation (PODD)
Here's Why Insulet (PODD) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Insulet (PODD) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Insulet Corporation (PODD) Q1 2026 Earnings Call Transcript
Insulet Corporation (PODD) Q1 2026 Earnings Call Transcript
Insulet (PODD) Loses 17.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Insulet (PODD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Insulet (PODD) Q1 Earnings and Revenues Top Estimates
Insulet (PODD) came out with quarterly earnings of $1.42 per share, beating the Zacks Consensus Estimate of $1.14 per share. This compares to earnings of $1.02 per share a year ago.
Insulet lifts annual revenue forecast after quarterly beat on strong insulin pump demand
Insulet raised its annual revenue growth forecast on Wednesday after reporting better-than-expected quarterly results, driven by strong demand for its tubeless insulin pumps that eliminate the need for daily injections.
Insulet (PODD) is an Incredible Growth Stock: 3 Reasons Why
Insulet (PODD) possesses solid growth attributes, which could help it handily outperform the market.
Insulet (PODD) Upgraded to Buy: Here's Why
Insulet (PODD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Insulet (PODD) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should You Continue to Hold Insulet Stock in Your Portfolio?
PODD's Omnipod 5 momentum and strong growth outlook highlight upside, but macro pressures and rising competition could challenge its near-term performance.
Insulet (PODD) Down 8.2% Since Last Earnings Report: Can It Rebound?
Insulet (PODD) reported earnings 30 days ago. What's next for the stock?
